Skip to main content Help with accessibility Skip to main navigation

PSORIASIS in adults, sequential use of biological agents

Last Updated: 22 May 2019

Body System: Skin


The Pan Mersey Area Prescribing Committee recommends the sequential use of biological agents, adalimumab, brodalumab, certolizumab, etanercept, guselkumab, infliximab, ixekizumab, secukinumab, tildrakizumab and ustekinumab, in the management of psoriasis according to the attached flowchart.